Jan 11, 2025 · Gilead Will Have Exclusive Global Rights to the STAT6 Program, and LEO Pharma Will Have the Option to Co-Commercialize for Dermatology Indications Outside the U.S.

Jan 11, 2025 · Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders.

Jan 13, 2025 · Gilead will gain exclusive global rights to develop and commercialize LEO Pharma’s preclinical oral STAT6 program, which includes small molecule inhibitors and targeted protein degraders.

Jan 11, 2025 · Under this partnership, Gilead will acquire LEO Pharma’s comprehensive preclinical oral STAT6 small molecule inhibitors and targeted protein degraders. Gilead will lead further development...

Jan 11, 2025 · Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

Jan 11, 2025 · Gilead Sciences continues its divergence out of its original infectious disease beginnings and into cancer and, now, more deeply than before, into inflammation, penning a major $1.7 billion deal...

Jan 13, 2025 · To develop and market oral STAT6 inhibitors for inflammatory illnesses, Gilead Sciences (GILD, Financials) has teamed up with LEO Pharma for a $1.7 billion investment, the firms said Saturday.

Jan 13, 2025 · Gilead Sciences Inc. and LEO Pharma have partnered to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.

Jan 11, 2025 · (Reuters) - Gilead Sciences said on Saturday that it entered into a partnership with Denmark's LEO Pharma to develop programs to treat patients with inflammatory diseases.

Jan 12, 2025 · Gilead Sciences’ inflammation drug prospects have come via deals, and the latest one brings drug candidates for an elusive target that’s in pursuit by a growing number of companies. The drugmaker...